Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Early life exposure to PFAS associated with common childhood leukemia

Early exposure to PFAS, a group of widely used compounds known as "forever chemicals," was associated with a higher risk of acute lymphoblastic leukemia, the most common childhood cancer, according to University of California, Irvine Joe C. Wen School of Population & Public Health researchers.

27 Apr 2026

New strategy boosts natural killer cells to fight cancer

Scientists have developed a strategy to boost the cancer-fighting power of natural killer (NK) cells, part of the immune system's first line of defense.

24 Apr 2026

Study maps the evolution of myeloid leukemia in children with Down syndrome

It may be possible to identify which pre-cancerous cells will develop into a rare type of blood cancer, due to new research showing that a single genetic change drives myeloid leukemia in children with Down syndrome.

23 Apr 2026

New target CD43 may improve leukemia immunotherapy outcomes

Macrophages, much like Alice of "Alice in Wonderland," recognize and consume tumor cells that display "eat me" surface markers.

11 Apr 2026

Study finds increasing rates of therapy-related acute myeloid leukemia

Some therapies used to treat cancer may increase the risk of later developing cancers that affect the blood.

6 Apr 2026

Fertility treatments linked to small increases in some cancers

Findings indicate small increases in certain cancers linked to assisted reproduction, though overall cancer incidence aligns with the general female population.

13 Mar 2026

Trial highlights promising frontline therapy for blastic plasmacytoid dendritic cell neoplasm

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, according to new data from the Phase I/II multicenter international CADENZA trial led by researchers at The University of Texas MD Anderson Cancer Center.

11 Feb 2026

New study exposes a targetable vulnerability in acute myeloid leukemia

New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia by identifying the blood cancer's reliance on a specific signaling pathway involved in the body's inflammation response.

19 Jan 2026

Newly identified rare genetic variant reduces the risk of leukemia

A newly identified and rare genetic variant slows the growth of mutated blood stem cells, researchers report, and it reduces the risk of leukemia.

2 Jan 2026

Combination therapy offers hope for AML patients facing drug resistance

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common frontline therapies.

30 Dec 2025

Combining inhibitors and chemotherapy enhances treatment for aggressive leukemia subtypes

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, existing options do not lead to favorable clinical outcomes in all patients.

12 Dec 2025

Researchers identify chromatin accessibility changes driving stem cell transformation in MDS

Over the past few decades, advances in hematology have illuminated how a delicate balance between stem cell self-renewal and differentiation sustains healthy blood formation.

12 Dec 2025

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two aggressive blood cancers at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

People exposed to Agent Orange face higher risk of developing myelodysplastic syndrome

A new national study shows for the first time that people exposed to Agent Orange face a higher risk of developing myelodysplastic syndrome (MDS), tend to develop it earlier, and often have more aggressive disease that is more likely to progress to acute myeloid leukemia.

9 Dec 2025

Highly sensitive CRISPR-based method designed to detect low-frequency cancer mutations

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA circulating in the blood.

9 Dec 2025

Timing of genetic mutation dictates childhood leukemia aggressiveness

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same leukemia-causing gene mutation can have dramatically different outcomes: it depends on when in development the mutation first occurs.

8 Dec 2025

Aza-ven shows superior outcomes compared to induction chemotherapy in AML patients

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy.

7 Dec 2025

Black patients with AML experience earlier onset and poorer outcomes

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more than 20% more likely to die of any cause, according to an analysis of data conducted over a 34-year period and supported by the National Cancer Institute (NCI) is a component of the U.S. National Institutes of Health.

7 Dec 2025

A new generation of AML treatments brings hope for better survival

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates.

1 Dec 2025

New medication offers potential treatment for patients with deadliest form of blood cancer

Biomedical research that began at the University of Virginia School of Medicine has yielded a much-needed new treatment for patients with the deadliest form of blood cancer.

25 Nov 2025